Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 109 recruiting now early-phase tilt #27 of 28,707 conditions

HIV: early-phase trial registry

109 of 304 indexed HIV trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #27 of 28,707 conditions by registered trial count.

304 US clinical trials · 109 currently recruiting · #27 of 28,707 conditions by registered trial count

HIV: 304 US clinical trials tracked, 109 recruiting.

HIV is the subject of 304 registered US clinical trials on ClinicalTrials.gov, 109 of them currently open to new participants. 25 are in Phase 3-4 (later-stage) and 64 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 24 of these trials.

Enrollment posture brief

Registry condition hiv

OPEN 109 | RECR 36% | LATE 25 | EARLY 64 | RANK #27 | SPON 24

Nearest open-share peer: Acute Respiratory Failure (36% recruiting · 14 trials)

Acute Myeloid Leukemia51.8%Chronic Pain46%Cardiovascular Diseases44.1%HIV (this)36%COVID-1922.7%
Open-enrollment share among volume-matched conditions near HIV

HIV lists 109 open slots (36% of 304 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for HIV on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. HIV recruits in line with its size-band peers.

    109 of 304 indexed trials (35.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of HIV trials is spread across many organizations.

    National Institute of Allergy and Infectious Diseases (NIAID) accounts for 24 of 304 trials (7.9%). 115 distinct sponsors appear on at least one study for this condition label.

  3. Typical HIV enrolment sits around 100 participants.

    Median target enrolment is 100 among the 304 trials that report a genuine target (sentinel values excluded). 142 of those (46.7%) plan for fewer than 100 participants.

  4. HIV research is mostly interventional.

    252 interventional and 52 observational studies make up this index (82.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 132Phase 232Phase 312Phase 413

Phase Distribution

PhaseTrial count
Phase 1 32
Phase 2 32
Phase 3 12
Phase 4 13

Named interventions

Most-linked intervention names on HIV records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
10 trials
E/C/F/TAF Drug
3 trials
Varenicline Drug
3 trials
Atripla Drug
2 trials
Stribild Drug
2 trials
2GETHER Behavioral
2 trials
Brief Advice Behavioral
2 trials
Neuropsychological testing Behavioral
2 trials

US sites by state

Facility locations filed on HIV trials. A trial with sites in several states counts in each.

California 65 trials
Maryland 50 trials
New York 44 trials
Florida 40 trials
Massachusetts 37 trials
Alabama 22 trials
Pennsylvania 21 trials
North Carolina 21 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this HIV page

304 registered trials, 109 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HIV condition card totals 304 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.